Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2013-10-22 Major Shareholding Noti…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Change in substantial holding 5 pages 72.7KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 notice under the Corporations Act 2001, which reports changes in interests of a substantial shareholder in Pharmaxis Limited. It details previous and present voting power, changes in relevant interests, and includes transaction dates and share quantities. The document is a regulatory filing notifying the market and company of changes in major shareholdings, not a financial report or announcement of a report. This fits the definition of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notice, not just an announcement or certification.
2013-10-22 English
Change in substantial holding 5 pages 66.4KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interest of substantial shareholder under the Corporations Act 2001. It details changes in voting power and shareholdings of a substantial holder in Pharmaxis Limited. The content is focused on shareholding notifications and changes in substantial ownership, with no financial statements or management commentary. This matches the definition of a Major Shareholding Notification (MRQ). The document length and detail confirm it is the actual notice, not just an announcement or certification.
2013-10-21 English
Notice of Annual General Meeting/Proxy Form 10 pages 539.7KB
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF THE 2013 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT OF PHARMAXIS LTD' and contains detailed information about the upcoming AGM, including the date, location, agenda items such as financial statements, remuneration report, re-election of a director, and grant of performance rights. It also includes proxy voting instructions, voting restrictions, and explanatory notes on the items to be considered at the meeting. The document does not contain the actual financial statements or reports but refers to the 2013 annual report being available elsewhere. The content is consistent with a notice and explanatory statement for an AGM rather than the full annual report or other filings. Therefore, the document fits the category of AGM Information (AGM-R). The document length (15,000 characters) is substantial and contains detailed meeting information, supporting a high confidence classification.
2013-10-20 English
Appendix 4C - quarterly 5 pages 105.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and includes detailed financial data such as consolidated statement of cash flows, cash reconciliation, and payments to directors for the quarter ended 30 September 2013. It contains substantive financial data and analysis for a quarterly period, which aligns with the definition of an Interim / Quarterly Report (IR). The document is 14,571 characters long, indicating it is a full report rather than a brief announcement or certification. There is no indication that this is an announcement of a report or a certification letter, so it should be classified as an Interim / Quarterly Report. Q1 2013
2013-10-15 English
Pharmaxis Quarterly Investor Briefing 27 pages 343.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Investor Briefing' and contains detailed financial data for the three months ended 30 September 2013, including unaudited income statements, cash flow information, balance sheet data, and sales performance by region and product. It includes forward-looking statements, business plans, marketing updates, and detailed quarterly financial results. The presence of comprehensive financial statements and analysis for a quarter, along with operational and strategic updates, indicates this is a quarterly financial report rather than a brief earnings release or an investor presentation. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2013
2013-10-15 English
PHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL 1 page
Call Transcript Classification · 90% confidence The document is a media release announcing a quarterly investor conference call scheduled for 17 October 2013. It mentions that an investor presentation will be lodged prior to the call and provides telephone and online access details. The document does not contain any financial data, detailed financial statements, or substantive analysis itself. It is essentially an announcement of an upcoming conference call event, not the transcript or the presentation itself. Therefore, the document fits the category of a Call Transcript announcement or invitation, but since it is only announcing the call and not providing the transcript, it is best classified as a Call Transcript (CT) type document, as it relates directly to the conference call event. Confidence is high given the clear description and context.
2013-10-14 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.